Shortly after Alkermes and Avadel announced their deal, Lundbeck made an unsolicited offer of $23 per share, including $21 ...

Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high ...

Pfizer Inc (NYSE:PFE) is preparing to broaden its presence in the global obesity market, with a particular emphasis on ...

Investing.com -- Pfizer Inc plans to expand its obesity portfolio globally with a focus on oral medications following its Metsera acquisition, Chief Financial Officer Dave Denton said at the Jefferies ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Under the agreement, Kretinsky’s EPH will receive TotalEnergies stock equal to that amount, the French energy giant said in a ...

Just one month into his job, Novo Nordisk’s new chief executive went to bed one night in September thinking he had secured a ...

Pfizer Inc. has announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical ...